Gilead Sciences Inc. (GILD) shares soared 5.32% in after-hours trading on Tuesday, following the company's better-than-expected fourth quarter results and an upbeat outlook for 2025.
The biopharmaceutical company reported Q4 non-GAAP earnings of $1.90 per diluted share, exceeding analysts' expectations of $1.74. Revenue for the quarter rose 6% year-over-year to $7.57 billion, also topping estimates of $7.15 billion.
Gilead's HIV product sales increased 16% to $5.45 billion in Q4, fueled by strong demand for Biktarvy which saw sales jump 21% to $3.8 billion. The company's oncology sales grew 10% to $843 million, driven by robust performance from cell therapy products like Yescarta and Tecartus, as well as cancer drug Trodelvy.
For full-year 2025, Gilead provided an optimistic outlook, projecting non-GAAP diluted EPS between $7.70 and $8.10 on product sales of $28.2 billion to $28.6 billion. This guidance topped Wall Street's expectations.
Gilead noted the potential launch of its investigational HIV prevention drug lenacapavir in summer 2025 as a key growth driver. The company also highlighted progress across its oncology pipeline and plans to drive efficiencies to boost shareholder returns.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.